News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Noonberg Sarah B.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/09/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
05/17/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on MARINUS PHARMACEUTICALS, INC.
Txns:
| Granted 7,200 shares
@ $0 Granted 32,400 options to buy
@ $8.51, valued at
$275.7k
|
|
01/18/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/13/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/29/2020 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 15,000 options to buy
@ $16.54, valued at
$248.1k
|
|
05/07/2020 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $12.84, valued at
$321k
|
|
10/15/2019 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $2.82, valued at
$62k
|
|
06/11/2019 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 12,000 options to buy
@ $11.8, valued at
$141.6k
|
|
06/12/2018 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 12,000 options to buy
@ $6.98, valued at
$83.8k
|
|
12/19/2017 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 24,000 options to buy
@ $17.57, valued at
$421.7k
|
|
05/18/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|